July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Effectiveness of Trehalose 3% as a treatment for Dry Eye Syndrome in patients with Sjögren's Syndrome
Author Affiliations & Notes
  • Alejandro Navas
    Cornea and Refractive Surgery, Institute of Ophthalmology "Conde de Valenciana", Mexico City, CDMX, Mexico
  • Ariadna Benitez-García
    Cornea and Refractive Surgery, Institute of Ophthalmology "Conde de Valenciana", Mexico City, CDMX, Mexico
  • CHRISTIAN DENISSE PINKUS HERRERA
    Cornea and Refractive Surgery, Institute of Ophthalmology "Conde de Valenciana", Mexico City, CDMX, Mexico
  • Juan Carlos Serna-Ojeda
    Cornea and Refractive Surgery, Institute of Ophthalmology "Conde de Valenciana", Mexico City, CDMX, Mexico
  • Arturo J Ramirez-Miranda
    Cornea and Refractive Surgery, Institute of Ophthalmology "Conde de Valenciana", Mexico City, CDMX, Mexico
  • Enrique O Graue-Hernandez
    Cornea and Refractive Surgery, Institute of Ophthalmology "Conde de Valenciana", Mexico City, CDMX, Mexico
  • Footnotes
    Commercial Relationships   Alejandro Navas, Alcon Laboratories (C), Grin/Lupin Pharmaceuticals (C), STAAR Surgical (R), Théa Laboratoires (C); Ariadna Benitez-García, None; CHRISTIAN DENISSE PINKUS HERRERA, None; Juan Carlos Serna-Ojeda, None; Arturo Ramirez-Miranda, Carl Zeiss Meditec (C), Théa Laboratoires (C); Enrique Graue-Hernandez, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 915. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alejandro Navas, Ariadna Benitez-García, CHRISTIAN DENISSE PINKUS HERRERA, Juan Carlos Serna-Ojeda, Arturo J Ramirez-Miranda, Enrique O Graue-Hernandez; Effectiveness of Trehalose 3% as a treatment for Dry Eye Syndrome in patients with Sjögren's Syndrome. Invest. Ophthalmol. Vis. Sci. 2018;59(9):915.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the signs and symptoms of patients with dry eye and Sjögren's Syndrome that received Threalose 3% as a co-adjuvant treatment.

Methods : We analyzed the results of treatment with threalose 3% in patients from Mexico City, Mexico. The subjective evaluation included the OSDI Test, and the objective evaluation included Schirmer’s test, the tear break-up time (TBUT) and grading of corneal and conjunctival staining with the Oxford system. All evaluations were performed before treatment, and at three days, one week and two weeks after initiation of threalose. A paired t-test was performed between initial and the post treatment evaluations.

Results : Twenty-three patients (46 eyes) with a median age of 54 years (range 30 to 76 years) were included. 20 of the patients were females (88.4%) and 13 patients (56.5%) had Sjögren's syndrome secondary to another autoimmune disease, the most common being Rheumatoid Arthritis.
OSDI test presented a basal mean of 48.18 points (± 17.32 points) compared with a mean 40.29 points (± 14.57 points) after two weeks, showing an improvement of 7.89 points in the subjective evaluation (p=0.0003). Shirmer's test showed a non-statistically significant improvement from basal mean measurement of 3.97 mm (± 3.90 mm) compared with a mean 5.37 mm (± 4.88 mm) with a 1.40 mm increase in tear production after two weeks (p=0.2067). The initial TBUT was 4.67 seconds (± 3.19 seconds), which improved to 5.30 seconds (± 3.60 seconds), which showed an increase of 0.7 seconds (p=0.05). Finally, the Oxford system changed from an initial mean grade III to a grade II after 2 weeks of treatment (p<0.001).

Conclusions : Threalose 3% therapy in patients with dry eye secondary to Sjögren's Syndrome, showed an improvement in both signs and symptoms.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×